Temporally distinct and ligand-specific recruitment of nuclear receptor-interacting peptides and cofactors to subnuclear domains containing the estrogen receptor.
暂无分享,去创建一个
Y. Wan | J. Baxter | S. Nordeen | R. Day | F. Schaufele | D. McDonnell | Ching-Yi Chang | D. McDonnell | W. Liu | Weiqun Liu | C. Chang | R. N. Day
[1] J. Northrop,et al. Selection of Estrogen Receptor β- and Thyroid Hormone Receptor β-Specific Coactivator-Mimetic Peptides Using Recombinant Peptide Libraries , 2000 .
[2] S. Mosselman,et al. Antiestrogens specifically up-regulate bone morphogenetic protein-4 promoter activity in human osteoblastic cells. , 2000, Molecular endocrinology.
[3] Carolyn L. Smith,et al. Subnuclear Trafficking of Estrogen Receptor-α and Steroid Receptor Coactivator-1 , 2000 .
[4] T. Pederson,et al. Half a century of "the nuclear matrix". , 2000, Molecular biology of the cell.
[5] D. Fowlkes,et al. Dissection of the LXXLL Nuclear Receptor-Coactivator Interaction Motif Using Combinatorial Peptide Libraries: Discovery of Peptide Antagonists of Estrogen Receptors α and β , 1999, Molecular and Cellular Biology.
[6] B. Katzenellenbogen,et al. Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor. , 1999, Molecular endocrinology.
[7] R. Evans,et al. Regulation of Hormone-Induced Histone Hyperacetylation and Gene Activation via Acetylation of an Acetylase , 1999, Cell.
[8] D. Fowlkes,et al. Peptide antagonists of the human estrogen receptor. , 1999, Science.
[9] S. Cummings,et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. , 1999, JAMA.
[10] F. Schaufele. Regulation of estrogen receptor activation of the prolactin enhancer/promoter by antagonistic activation function-2-interacting proteins. , 1999, Molecular endocrinology.
[11] M. Morrow,et al. Tamoxifen, raloxifene, and the prevention of breast cancer. , 1999, Endocrine reviews.
[12] Paul Tempst,et al. Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex , 1999, Nature.
[13] H Grøn,et al. Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[14] G. Hager,et al. Differential localization and activity of the A- and B-forms of the human progesterone receptor using green fluorescent protein chimeras. , 1999, Molecular endocrinology.
[15] J. Davie,et al. Direct visualization of the human estrogen receptor alpha reveals a role for ligand in the nuclear distribution of the receptor. , 1999, Molecular biology of the cell.
[16] David A. Agard,et al. The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.
[17] Osborne Ck,et al. Tamoxifen in the Treatment of Breast Cancer , 1998 .
[18] C. Glass,et al. Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation. , 1998, Genes & development.
[19] R J Fletterick,et al. Structure and specificity of nuclear receptor-coactivator interactions. , 1998, Genes & development.
[20] B. Katzenellenbogen,et al. Estrogen receptor activation function 1 works by binding p160 coactivator proteins. , 1998, Molecular endocrinology.
[21] R. Day,et al. Visualization of Pit-1 transcription factor interactions in the living cell nucleus by fluorescence resonance energy transfer microscopy. , 1998, Molecular endocrinology.
[22] G. Stein,et al. Interrelationships of nuclear structure and transcriptional control: Functional consequences of being in the right place at the right time , 1998, Journal of cellular biochemistry.
[23] R. Roeder,et al. The TRAP220 component of a thyroid hormone receptor- associated protein (TRAP) coactivator complex interacts directly with nuclear receptors in a ligand-dependent fashion. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[24] R J Fletterick,et al. Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. , 1998, Science.
[25] G. Colditz,et al. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. , 1998, Journal of the National Cancer Institute.
[26] D. Pearce,et al. Subcellular localization of mineralocorticoid receptors in living cells: effects of receptor agonists and antagonists. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[27] M. Stallcup,et al. Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different binding specificities. , 1998, Molecular endocrinology.
[28] Zbigniew Dauter,et al. Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.
[29] J. Baxter,et al. Activities in Pit-1 determine whether receptor interacting protein 140 activates or inhibits Pit-1/nuclear receptor transcriptional synergy. , 1997, Molecular endocrinology.
[30] David M. Heery,et al. A signature motif in transcriptional co-activators mediates binding to nuclear receptors , 1997, Nature.
[31] M. Garabedian,et al. GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors , 1997, Molecular and cellular biology.
[32] E. Kalkhoven,et al. AF-2 activity and recruitment of steroid receptor coactivator 1 to the estrogen receptor depend on a lysine residue conserved in nuclear receptors , 1997, Molecular and cellular biology.
[33] V. Jordan,et al. Risks and benefits of tamoxifen therapy. , 1997, Oncology.
[34] G. Hager,et al. Visualization of glucocorticoid receptor translocation and intranuclear organization in living cells with a green fluorescent protein chimera. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[35] M. Stallcup,et al. GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[36] R. Tsien,et al. Engineering green fluorescent protein for improved brightness, longer wavelengths and fluorescence resonance energy transfer , 1996, Current Biology.
[37] B. Katzenellenbogen,et al. Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. , 1996, Molecular endocrinology.
[38] B. O’Malley,et al. Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily , 1995, Science.
[39] B. van Steensel,et al. Localization of the glucocorticoid receptor in discrete clusters in the cell nucleus. , 1995, Journal of cell science.
[40] P. Kushner,et al. Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. , 1995, The EMBO journal.
[41] M. Gossen,et al. Transcriptional activation by tetracyclines in mammalian cells. , 1995, Science.
[42] R. Fletterick,et al. The Molecular Biology of Thyroid Hormone Action , 1995, Annals of the New York Academy of Sciences.
[43] P. Webb,et al. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. , 1995, Molecular endocrinology.
[44] J. Lees,et al. Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. , 1992, The EMBO journal.
[45] M. Ko,et al. The dose dependence of glucocorticoid‐inducible gene expression results from changes in the number of transcriptionally active templates. , 1990, The EMBO journal.
[46] S. Legha,et al. Tamoxifen in the treatment of breast cancer. , 1988, Annals of internal medicine.
[47] C. Benham,et al. Transcriptional augmentation: modulation of gene expression by scaffold/matrix-attached regions (S/MAR elements). , 2000, Critical reviews in eukaryotic gene expression.
[48] K. Brown. Nuclear structure, gene expression and development. , 1999, Critical reviews in eukaryotic gene expression.
[49] Dana,et al. Estrogen receptor (ER) modulators each induce distinct conformational changes in ER a and ER b , 1999 .
[50] H. Gronemeyer,et al. Therapeutic potential of selective modulators of nuclear receptor action. , 1998, Current opinion in chemical biology.
[51] J. Gustafsson,et al. Therapeutic potential of selective estrogen receptor modulators. , 1998, Current opinion in chemical biology.
[52] F. Schaufele. CCAAT/Enhancer-binding Protein (cid:97) Activation of the Rat Growth Hormone Promoter in Pituitary Progenitor GHFT1-5 Cells* , 1996 .
[53] B. O’Malley,et al. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. , 1994, Annual review of biochemistry.